Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Nephrology | Oncology | Pathology | Journal

Back to Journal Articles

Biomarker Found to Predict Therapy Benefit in Renal Cancer

Last Updated: August 15, 2012.

 

Lactate dehydrogenase significant prognostic biomarker in poor-risk renal cell carcinoma

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Pretreatment serum lactate dehydrogenase is a predictive biomarker for the survival benefit derived from treatment with the TORC1 inhibitor temsirolimus in patients with renal cell carcinoma, according to a study published online Aug. 13 in the Journal of Clinical Oncology.

WEDNESDAY, Aug. 15 (HealthDay News) -- Pretreatment serum lactate dehydrogenase (LDH) is a predictive biomarker for the survival benefit derived from treatment with the TORC1 inhibitor temsirolimus in patients with renal cell carcinoma (RCC), according to a study published online Aug. 13 in the Journal of Clinical Oncology.

To assess whether serum LDH is prognostic and has predictive value, Andrew J. Armstrong, M.D., from Duke University in Durham, N.C., and colleagues evaluated serum LDH (pretreatment and post-treatment) in 404 poor-risk patients with RCC receiving temsirolimus or interferon alfa treatment during participation in an international phase III randomized trial.

The researchers found that mean baseline serum normalized LDH was 1.23 times the upper limit of normal (ULN). For patients with LDH more than 1 × ULN, the multivariable hazard ratio for death was 2.81 (P < 0.001) compared to patients with LDH ≤1 × ULN. Overall survival was significantly improved with temsirolimus (6.9 versus 4.2 months) among the 140 patients with LDH above the ULN. However, overall survival was not significantly improved with temsirolimus compared with interferon therapy among the 264 patients with normal LDH (11.7 and 10.4 months, respectively; P = 0.514).

"Serum LDH is a prognostic and a predictive biomarker for the survival benefit conferred by TORC1 inhibition in poor-risk RCC," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Pfizer, which provided funding to the authors' institution and manufactures temsirolimus.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Immune Response to Hep A Vaccine Persists in Children Next: ABO Blood Group Correlated With Coronary Heart Disease

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.